Categories: All postsCannabis

HEXO is significantly undervalued, says Beacon Securities

Canadian cannabis play HEXO Corp (HEXO Stock Quote, Chart TSX:HEXO) just closed on the acquisition of Newstrike Brands, an event which Beacon Securities analyst Russell Stanley is treating as a positive for the stock. In a client update on Monday, Stanley has reiterated his “Buy” recommendation and $14.00 target, which represented a projected return of 36 per cent at the time of publication.

Last Friday, HEXO and Newstrike announced the closing of the previously-announced all-stock deal, with HEXO to issue 0.06332 shares per share of Newstrike, amounting to $321 million at current prices ($263 million at the time of original announcement).

Stanley says, “This acquisition expands HEXO’s aggregate annualized cultivation capacity from 108,000kg to 150,000kg and it adds sales relationships with Alberta, Saskatchewan, Manitoba, Nova Scotia, PEI and New Brunswick. This gives HEXO sales relationships in all Canadian provinces, excluding Newfoundland and Labrador. As we believe that only three companies have sales relationships into all ten provinces, HEXO is extremely well-positioned relative to the pack.”

Stanley says that an update from management on its fiscal third quarter (due in early June) should be supportive of the stock. Currently, management has called for flat revenues compared to its Q2.

The analyst contends that HEXO is now trading at 14x his C2020 EBITDA estimate, which would represent a 33-per-cent discount to the 22x average of its broader peer group, a 53-per-cent discount to the 31x average among companies with a plus-$1 billion market cap and a 71-per-cent discount to the 50x average for other US-listed cannabis companies.

“We therefore view HEXO as significantly undervalued, particularly given that it stands out amongst Canadian LPs for issuing formal revenue guidance (gross revenue of $479 million in F2020, or $400 million net of excise taxes). We continue to believe that HEXO is also uniquely positioned as a potential partner (and acquisition candidate) for CPG companies looking for a platform transaction for cannabis expansion,” Stanley writes.

The analyst is calling for fiscal 2019 revenue and Adjusted EBITDA of $59.5 million and negative $21.3 million.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: hexo
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Should you buy AMZN? (May, 2024)

Following the company's first quarter results, Roth MKM analyst Rohit Kulkarni has maintained his "Buy" rating on Amazon (Amazon Stock… [Read More]

13 hours ago

These cannabis stocks will benefit most from reclassification

It happened. The move that everyone in the cannabis sector was hoping for came about swiftly on the last day… [Read More]

20 hours ago

Is AMD stock a buy? (May, 2024)

Following the company's first quarter results, Roth MKM analyst Suji Desilva has maintained his "Buy" rating on Advanced Micro Devices… [Read More]

20 hours ago

Is Wolfspeed stock still a buy?

Ahead of the company's third quarter results, Roth MKM analyst Scott Irwin has maintained his "Buy" rating on Wolfspeed (Wolfspeed… [Read More]

21 hours ago

WELL Health inks five-year deal with Microsoft

It's become one of the biggest players in the Canadian healthcare space, now WELL Health (WELL Health Stock Quote, Chart,… [Read More]

2 days ago

Is Thomson Reuters stock a buy right now?

Its stock has made a since last October, but is there more upside left in Thomson Reuters (Thomson Reuters Stock… [Read More]

2 days ago